CA3090150A1 - Ahr modulators - Google Patents

Ahr modulators Download PDF

Info

Publication number
CA3090150A1
CA3090150A1 CA3090150A CA3090150A CA3090150A1 CA 3090150 A1 CA3090150 A1 CA 3090150A1 CA 3090150 A CA3090150 A CA 3090150A CA 3090150 A CA3090150 A CA 3090150A CA 3090150 A1 CA3090150 A1 CA 3090150A1
Authority
CA
Canada
Prior art keywords
methy1
pheny1
trifluoromethyl
ethy1
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3090150A
Other languages
English (en)
French (fr)
Inventor
Muzaffar Alam
Hilary Plake Beck
Michael Patrick Dillon
Marcos GONZALEZ-LOPEZ
James Clifford Sutton Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ideaya Biosciences Inc
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of CA3090150A1 publication Critical patent/CA3090150A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
CA3090150A 2018-02-06 2019-02-05 Ahr modulators Pending CA3090150A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862626739P 2018-02-06 2018-02-06
US62/626,739 2018-02-06
US201962793260P 2019-01-16 2019-01-16
US62/793,260 2019-01-16
PCT/US2019/016705 WO2019156987A1 (en) 2018-02-06 2019-02-05 AhR MODULATORS

Publications (1)

Publication Number Publication Date
CA3090150A1 true CA3090150A1 (en) 2019-08-15

Family

ID=65494575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3090150A Pending CA3090150A1 (en) 2018-02-06 2019-02-05 Ahr modulators

Country Status (10)

Country Link
US (3) US10815250B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219495A1 (cg-RX-API-DMAC7.html)
JP (1) JP7382348B2 (cg-RX-API-DMAC7.html)
CN (1) CN111683950B (cg-RX-API-DMAC7.html)
CA (1) CA3090150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749669T6 (cg-RX-API-DMAC7.html)
ES (1) ES2946632T7 (cg-RX-API-DMAC7.html)
FI (1) FI3749669T6 (cg-RX-API-DMAC7.html)
TW (1) TWI840343B (cg-RX-API-DMAC7.html)
WO (1) WO2019156987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
KR20260057216A (ko) * 2019-11-22 2026-04-27 세일 바이오메디슨스, 인크. Ahr 길항제로서의 피리도피리미디논 유도체
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022081649A1 (en) * 2020-10-13 2022-04-21 Senda Biosciences, Inc. Biomarkers related to immune checkpoint inhibitor therapy and methods of using the same
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2454080A1 (en) 2001-08-13 2003-02-27 Robert Edward Detlefsen Ultraviolet light absorbers
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102105464A (zh) 2008-05-27 2011-06-22 德克萨斯大学系统董事会 Wnt蛋白信号转导抑制剂
MX2011009568A (es) 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
WO2010148350A1 (en) * 2009-06-18 2010-12-23 Cornell University Photoproducts of tryptophan, their synthesis and uses thereof
US10314810B2 (en) * 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US11427600B2 (en) * 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds

Also Published As

Publication number Publication date
CN111683950A (zh) 2020-09-18
EP4219495A1 (en) 2023-08-02
TWI840343B (zh) 2024-05-01
EP3749669A1 (en) 2020-12-16
FI3749669T6 (fi) 2024-11-13
US12258354B2 (en) 2025-03-25
JP2021512954A (ja) 2021-05-20
US20190270754A1 (en) 2019-09-05
JP7382348B2 (ja) 2023-11-16
US11407764B2 (en) 2022-08-09
ES2946632T7 (es) 2025-03-04
US20210002297A1 (en) 2021-01-07
US20230039955A1 (en) 2023-02-09
US10815250B2 (en) 2020-10-27
FI3749669T3 (fi) 2023-05-26
TW201945362A (zh) 2019-12-01
WO2019156987A1 (en) 2019-08-15
ES2946632T3 (es) 2023-07-21
DK3749669T6 (da) 2024-11-18
EP3749669B1 (en) 2023-03-08
EP3749669B3 (en) 2024-09-04
DK3749669T3 (da) 2023-06-06
CN111683950B (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
JP7624476B2 (ja) A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
US12258354B2 (en) AhR modulators
JP7700196B2 (ja) A2a/a2b阻害剤としての縮合ピラジン誘導体
US11548867B2 (en) Amido compounds as AhR modulators
CA3200006A1 (en) Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors
US11530220B2 (en) Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
JP2024505890A (ja) がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
HK40042159B (en) Ahr modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724